Napo Pharmaceuticals, Inc.
185 Berry Street
South San Francisco
85 articles with Napo Pharmaceuticals, Inc.
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (Mytesi®) on the gastrointestinal microbiome in people living with HIV/AIDS (PLWHA) has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3.
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
Napo Pharmaceuticals, Inc. (Napo), the wholly owned US subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the signing of a license agreement with Napo's Italian subsidiary, Napo EU S.p.A.
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
Napo Pharmaceuticals, Inc. announced today the completion of an additional preclinical toxicology study intended to support continued development of NP-300 (lechlemer) for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions.
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
Dragon SPAC S.p.A. and Napo EU S.p.A. announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros, representing the previously announced $10.8 million of funding from Jaguar into Dragon SPAC using funds from the recent registered direct offering for the benefit of Jaguar's wholly-owned Italian subsidiary.
Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
Napo Pharmaceuticals Inc., announced today the appointment of Darlene Horton, M.D., a biopharmaceutical veteran and leading clinical development expert, to the role of Chief Medical Officer (CMO) for Napo.
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc. Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4, 2021
Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total Potential of $17 Million
IQVIA™ (NYSE:IQV) today announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ innovative commercial solutions suite, to support Napo’s growing commercial organization and enable it to work more closely with healthcare providers.
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
RedHill has been grantedthe exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals, a subsidiary of Jaguar Health
Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), is deeply saddened by the passing of Dr. Mathilde Krim, Cofounder and Chairperson of the American Foundation for AIDS Research (amfAR).
Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results
Jaguar Health announced today that Company management will host a conference call on Monday, January 22, 2018 at 4:15 p.m. Eastern Time to provide updates regarding Jaguar and Napo Pharmaceuticals commercial, educational and product development activities and 2017 results.
Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger With Napo Pharmaceuticals
As stated in the 10-Q, Jaguar registered net income and comprehensive income of approximately $4.75 million in third quarter of 2017.
Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8M
The average monthly Mytesi sales from August through October of this year increased over 50% relative to average monthly Mytesi® sales that took place from January through July of 2017.
The call is being hosted to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals.
Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo's FDA-Approved Human Prescription Drug
Napo’s HIV Scientific Advisory Board will focus primarily on physician education, and community and global awareness regarding the importance and availability of solutions for neglected comorbidities.
Jaguar Health announced today that it will host a conference call on Tuesday, November 14, 2017 at 4:30 p.m. Eastern Time to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals, Inc. (Napo).
Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug
Jaguar Health announced today that its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has launched a significantly enhanced version of Mytesi.com, the website for Mytesi® (crofelemer),
Napo Pharmaceuticals Endorses Prevention Access Campaign's U=U Consensus Statement for People Living With HIV/AIDS (PLWHA)
Napo Pharmaceuticals announced today that it has joined more than 400 organizations from 59 countries in supporting the U=U Consensus Statement.
Jaguar Subsidiary Napo Pharmaceuticals, Inc. Files CMC Supplement With FDA For Sample-Size Bottles Of Mytesi, Napo’s FDA-Approved Human Drug, To Support Upcoming National Sample Campaign
Jaguar Subsidiary Napo Pharmaceuticals, Inc. And Glenmark Pharma Sign Agreement Returning Key Rights In 141 Countries To Napo, Solidifying Jaguar’s Global Commercial Control Of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug